On Monday, Pagaya (NASDAQ:PGY) Technologies (NASDAQ:PGY) experienced a decrease in its stock price target from $42.00 to $32.00, as announced by Canaccord Genuity. Despite the reduction, the firm maintains a Buy rating on the stock. The price target adjustment comes after Travere Therapeutics revealed a pause in patient enrollment for the Phase III HARMONY study of pegtibatinase in Homocystinuria (HCU) due to a manufacturing scale-up issue.
Travere's voluntary decision to halt new patient enrollment is linked to a technical difficulty encountered during the manufacturing process. However, this pause will not affect patients currently participating in the study, who will continue as planned. The company anticipates resuming enrollment in the year 2026.
The delay introduced by this manufacturing challenge is expected to push back the launch of pegtibatinase. Canaccord Genuity has revised their financial model to account for a two-year postponement in the product's anticipated launch in both the United States and the European Union markets. Originally projected for 2027 in the U.S. and 2028 in the EU, the new estimated launch dates are now 2029 and 2030, respectively.
The updated timeline for the HCU program has led to a reduction in the 12-month price target for Pagaya Tech, now set at $32, a slight decrease from the previous target of $33. This adjustment reflects the revised expectations for the pegtibatinase treatment's market entry and the consequent financial implications for the company.
In other recent news, Pagaya Technologies Ltd. has reported robust Q2 2024 earnings, with a network volume of $2.3 billion and a record $50 million in adjusted EBITDA. Despite a net loss of $75 million due to share-based compensation and fair value adjustments, the company has raised its full-year outlook, indicating strong growth in fee revenue less production costs and four consecutive quarters of positive operating cash flow.
Pagaya Technologies also signed a $1 billion forward flow agreement with Castlelake and achieved a AAA rating on its personal loan ABS program.
In terms of executive transitions, Scott Bower has stepped down as the principal accounting officer, with Nam Woo Kim taking over Bower's responsibilities on an interim basis. The company has also appointed Rajinder Singh, a veteran in the banking and financial services industry, as its new Chief Risk Officer.
Benchmark has initiated coverage of Pagaya shares with a Buy rating, projecting that the company's potential to self-fund its growth may lead to GAAP net income profitability by 2025. These are among the recent developments within Pagaya Technologies Ltd.
InvestingPro Insights
Recent InvestingPro data provides additional context to Pagaya Technologies' current market position. Despite the reduced price target from Canaccord Genuity, PGY's market cap stands at $715.28 million, with a revenue of $925.42 million in the last twelve months as of Q2 2024. The company has shown strong revenue growth, with a 27.98% increase in the most recent quarter.
InvestingPro Tips highlight that PGY is trading at a low revenue valuation multiple, which could be of interest to value-oriented investors. Analysts predict the company will be profitable this year, potentially offsetting concerns about the delayed launch of pegtibatinase.
However, it is worth noting that PGY's stock has taken a significant hit recently, with a -16.65% return over the past week and a -33.86% return over the last month. This volatility aligns with the InvestingPro Tip indicating that stock price movements are quite volatile.
For investors seeking a more comprehensive analysis, InvestingPro offers 7 additional tips for PGY, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.